Medical Technologies
USTR pressures Taiwan on pricing and reimbursement of pharmaceuticals and medical devices
Submitted by James Love on 6. March 2010 - 9:26This from USTR's 2010 Trade Policy Agenda and 2009 Annual Report:
UNDP ranks the U.S. 26ths in term of life expectancy at birth
Submitted by James Love on 21. November 2009 - 21:47As the U.S. considers health reform legislation, it is useful to review how countries rank in terms of life expectancy at birth.
From the 2009 UNDP Human Development Report statistical appendix:
Federal Support for research (Enbrel) etanercept, evidence from CRISP and Clinicaltrials.Gov
Submitted by James Love on 1. November 2009 - 22:51KEI was asked to look at federal support for research and development on (Enbrel) etanercept.
A November 1, 2009 search of the NIH CRISP database reports 167 federal grants for research on etanercept.
Request for Solidarity from Korea: Gleevec price reduction
Submitted by Judit Rius on 7. October 2009 - 10:12Korean civil society has asked KEI to disseminate this request for solidarity and action in their efforts to reduce the price of Gleevec, a leukemia treatment pill. The current price is approximately 2,300 USD per month for an adult patient and the Korean government has been sued by Novartis for trying to reduce the price a 14%. Korean civil society is also requesting Novartis to introduce a higher form, 400 mg, in Korea.
REQUEST for Solidarity:
The Right to Development Criteria, applied to TDR and the Global Fund
Submitted by James Love on 18. September 2009 - 5:50For several years, the UN Human Rights Council (HRC) has been working on mechanisms to implement a 1986 UN Resolution on the "Right to Development." To this end, the HRC has created a Working Group on the Right to Development, and a High Level Task Force On The Implementation Of The Right To Development.
Roll Call on Biogenerics
Submitted by James Love on 9. September 2009 - 14:19James K. Glassman and I published an article on biogenerics today in Roll Call.
KEI letter to WHO on EDL
KEI's March 2, 2007 letter to the Expert Committee on the Selection and Use of Essential Medicines is here .
Update: WHO released the new 15th Essential Medicines List on April 13th, 2007. The list adds two new patented drugs for HIV/AIDS. Without comment, however, the WHO did not adopt KEI's proposal to add a supplemental list of medications that would be included "if available at generic prices."
WHO Expert Working Group on R&D Financing (EWG)
Submitted by Staff on 1. September 2009 - 13:44WHO website on the EWG
NEWS: The EWG secretariat has released a draft evaluation framework, evaluation criteria and the inventory of financing proposals. The EWG is accepting public comments through the Second Web-based Public Hearing. Deadline: September 5 2009. KEI has offered critical comments on the criteria.
WIPO DG Francis Gurry highlights disability as a theme for Conference on Intellectual Property and Global Challenges
Submitted by thiru on 24. March 2009 - 8:39As mentioned in James Love’s blog today entitled Notes from Day One of WIPO SCP 13, the WIPO Standing Committee on the Law of Patents (SCP) is examining four key issues at its Thirteenth Session this week including Standards and Patents, Exclusions from Patentable Subject Matter and Exceptions and Limitations to the Rights, The Client-Attorney Privilege and Dissemination of Patent Information.
India: Intervention at WTO TRIPS Council on public health dimension of the TRIPS Agreement
Submitted by thiru on 9. March 2009 - 9:25On 3 March 2009, India delivered the following intervention at the WTO Council for TRIPS meeting on the issue of the public health dimension of the TRIPS Agreement in the context of the Dutch seizures.
_______________________________________________________________________
INTERVENTION by INDIA
Agenda item ‘M’ – OTHER BUSINESS – Public Health dimension of TRIPS Agreement
Chair,
